Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells

被引:3
|
作者
Tahara, Atsuo [1 ]
Tsukada, Junko [1 ]
Tomura, Yuichi [1 ]
Kusayama, Toshiyuki [1 ]
Momose, Kazuhiro [1 ]
Taniguchi, Nobuaki [1 ]
Suzuki, Takeshi [1 ]
Yatsu, Takeyuki [1 ]
Shibasaki, Masayuki [1 ]
机构
[1] Astellas Pharma Inc, Inst Drug Discovery Res, Tsukuba, Ibaraki 3002698, Japan
关键词
vasopressin; V-1A receptor; YM218; mesangial cells;
D O I
10.1159/000095698
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vasopressin (AVP) causes mesangial cell contraction, proliferation and hypertrophy. The present study investigated the effects of YM218, a potent, nonpeptide AVP V-1A receptor-selective antagonist, on rat mesangial cells using binding, signal transduction and cell growth assays. Specific binding of H-3-AVP to rat mesangial cell plasma membranes was dependent upon time, temperature and membrane protein concentration. Scatchard plot analysis of equilibrium binding data revealed the existence of a single class of high-affinity binding sites with the expected V-1A receptor profile. YM218 showed high affinity for V-1A receptors, exhibiting a K-i value of 0.19 nmol/l. AVP concentration-dependently increased intracellular Ca2+ ([Ca2+](i)) levels, stimulated mitogen-activated protein (MAP) kinase and induced hyperplasia. Conversely, YM218 potently suppressed [Ca2+](i) elevation, activation of MAP kinase and hyperplasia induced by AVR These results indicate that YM218 displays both high affinity for rat mesangial cell V-1A receptors and high potency in inhibiting AVP-induced signal transduction and growth response. Therefore, YM218 is a useful pharmacologic tool for investigating the physiologic and pathophysiologic roles of AVP in kidney, and may have clinical application in the prevention or regression of mesangial cell growth. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:81 / 90
页数:10
相关论文
共 12 条
  • [1] Effect of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy
    Tahara, Atsuo
    Tsukada, Junko
    Tomura, Yuichi
    Suzuki, Takeshi
    Yatsu, Takeyuki
    Shibasaki, Masayuki
    VASCULAR PHARMACOLOGY, 2007, 46 (06) : 463 - 469
  • [2] Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells
    Tahara, A
    Tsukada, J
    Tomura, Y
    Momose, K
    Suzuki, T
    Yatsu, T
    Shibasaki, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 538 (1-3) : 32 - 38
  • [3] Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
    Tahara, A
    Tsukada, J
    Tomura, Y
    Kusayama, T
    Wada, KI
    Ishii, N
    Taniguchi, N
    Suzuki, T
    Yatsu, T
    Uchida, W
    Shibasaki, M
    PHARMACOLOGICAL RESEARCH, 2005, 51 (03) : 275 - 281
  • [4] Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist
    Tsukada, J
    Tahara, A
    Tomura, Y
    Kusayama, T
    Wada, K
    Ishii, N
    Taniguchi, N
    Suzuki, T
    Yatsu, T
    Uchida, W
    Shibasaki, M
    VASCULAR PHARMACOLOGY, 2005, 42 (02) : 47 - 55
  • [5] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [6] Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor
    Nakamura, Y
    Haneda, T
    Osaki, J
    Miyata, S
    Kikuchi, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 391 (1-2) : 39 - 48
  • [7] Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells
    Tsukada, J
    Tahara, A
    Tomura, Y
    Wada, K
    Kusayama, T
    Ishii, N
    Yatsu, T
    Uchida, W
    Taniguchi, N
    Tanaka, A
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (05) : 746 - 754
  • [8] Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors
    Tahtaoui, C
    Balestre, MN
    Klotz, P
    Rognan, D
    Barberis, C
    Mouillac, B
    Hibert, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) : 40010 - 40019
  • [9] Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain:: An in vitro and in vivo autoradiographic study
    Tribollet, E
    Raufaste, D
    Maffrand, JP
    NEUROENDOCRINOLOGY, 1999, 69 (02) : 113 - 120
  • [10] Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions
    Tahara, Atsuo
    Tsukada, Junko
    Tomura, Yuichi
    Yatsu, Takeyuki
    Shibasaki, Masayuki
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (05): : 438 - 446